T. Zander, M. Scheffler, L. Nogova, C. Kobe, W. EngelRiedel, M. Hellmich, I. Papachristou, K. Toepelt, A. Draube, L. Heukamp, R. Buettner, Y. D. Ko, R. T. Ullrich, E. Smit, R. Boellaard, A. A. Lammertsma, M. Hallek, A. H. Jacobs, A. Schlesinger, K. Schulte, S. Querings, E. Stoelben, B. Neumaier, R. K. Thomas, M. Dietlein and J. Wolf, “Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib by Using [18F] Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography,” Journal of Clinical Oncology, Vol. 29, No. 13, 2011, pp. 1701-1708. doi:10.1200/JCO.2010.32.4939

has been cited by the following article:

• TITLE: A model System for Validation of PET Radiopharmaceuticals: Focusing on Tumor Microenvironment

  AUTHORS: Xiao-Feng Li, Huijie Jiang, Yuanyuan Ma, Tao Huang, Xindao Yin, A. Cahid Civelek, Baozhong Shen

  KEYWORDS: 18F-Fluoro-2-Deoxyglucose; 18F-Fluorothymidine; 18F-Misonidazole; Microenvironment; Hypoxia; Proliferation

  JOURNAL NAME: International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, Vol.2 No.1, February 26, 2013

  ABSTRACT: Positron emission tomography (PET) imaging has emerged as an important clinical tool for cancer management, and specifically targeted radiopharmaceuticals play critical roles on PET molecular imaging. Solid cancers have highly complex and heterogeneous microenvironment, this review focused on those microenvironmental factors such as hypoxia, proliferation and perfusion and, accordingly, a novel test system for validation of current and novel targeted imaging radiopharmaceuticals. In this review, we have introduced the establishment of cancer and metastases models in nude mice, visualization of microenvironmental components of hypoxia, proliferation, perfusion, stroma and necrosis in cancers and metastases for establishing the microenvironment based model system, and validation of several radio- pharmaceuticals such as 18F-fluoro-2-deoxyglucose (18F-FDG) 18F-fluorothymidine (18F-FLT), 18F-misonidazole (18F- FMISO) using the system. We found that 18F-FLT accumulates in proliferating cancer cells, while 18F-FMISO and 18F-FDG mostly accumulate in hypoxic and non-proliferative cancer cells, 18F-FDG shares roughly similar intratumoral distribution pattern with 18F-FMISO and IAZGP, but mutually excludes 18F-FLT. This model system validated current tracers for imaging glucose metabolism, hypoxia and proliferation in cancer and metastases, therefore, can be used for novel targeted radiopharmaceuticals validation.